International heart journal最新文献

{"title":"Chrysophanol Mitigates Chronic Heart Failure in Rats by Modulating ROS-Mediated Parthanatos and Pyroptosis.","authors":"Mengjiao Zhu, Sichao Tai","doi":"10.1536/ihj.24-387","DOIUrl":"10.1536/ihj.24-387","url":null,"abstract":"<p><p>Chronic heart failure (CHF) triggers a cascade of events involving parthanatos and pyroptosis, culminating in cellular malfunction, inflammation, and tissue degeneration. This study aims to inquire into the inherent mechanism of chrysophanol (CHR) in the treatment of CHF.In vitro, we cultured the rat embryonic cardiomyocyte cell line H9c2. Parthanatos was initiated through N-methyl-N'-nitro-N'-nitrosoguanidine (MNNG) induction, followed by treatment with varying concentrations of CHR. The evaluation of parthanatos and pyroptosis in cardiomyocytes was assessed by western blotting. In vivo, the transverse aortic constriction (TAC) model was used to simulate CHF. The hemodynamic indices were performed to evaluate cardiac function in rats. The degree of inflammatory cell infiltration and fibrosis within cardiac tissue was assessed using hematoxylin and eosin staining and Masson's trichrome staining, respectively. Cardiac tissues were obtained and subjected to immunohistochemical analysis to assess PARP-1 expression. Subsequently, dual immunofluorescence staining (caspase-1 and NLRP3) was conducted, aiming to comprehensively evaluate the status of parthanatos and pyroptosis in the cardiac tissues of rats.In contrast to the MNNG or TAC group, the groups administered with CHR exhibited an inhibitory effect on Reactive oxygen species (ROS) expression, as well as parthanatos and pyroptosis proved by cell and animal experiments (P < 0.05). The reduced expression of PAR, PARP-1, AIF, NLRP3, IL-1β, caspase-1, and cleaved-GSDMD compared with the MNNG or TAC group proved it (P < 0.05). Moreover, compared with the TAC group, CHR significantly improved the cardiac histology of TAC rats. These findings collectively suggested the potential of CHR in ameliorating CHF.CHR may mitigate CHF in rats by modulating ROS-mediated parthanatos and pyroptosis.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 1","pages":"126-136"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Fungal Prosthetic Valve Endocarditis Complicated by Embolic ST-Elevated Myocardial Infarction.","authors":"Yudai Tanaka, Yuki Saito, Riku Arai, Nobuhiro Murata, Masashi Tanaka, Yasuo Okumura","doi":"10.1536/ihj.24-583","DOIUrl":"10.1536/ihj.24-583","url":null,"abstract":"<p><p>Acute coronary syndrome (ACS) is a rare complication of infective endocarditis (IE) and is associated with high mortality. Typically, coronary artery occlusion is a complication of bacterial autologous valve IE. We present the case of a 74-year-old woman with a history of aortic valve replacement for aortic stenosis who was receiving immunosuppressive therapy for rheumatoid arthritis. Upon admission, she was diagnosed with ST-elevation myocardial infarction (STEMI), and coronary angiography (CAG) revealed complete occlusion in the terminal branches of the left circumflex coronary artery (LCX #12 and #14). On day 3 of admission, three-dimensional transesophageal echocardiography (3D-TEE) was performed, and vegetation was detected, leading to IE diagnosis.The patient underwent prosthetic valve replacement on day 4. Subsequent blood cultures grew Candida albicans, and histopathological examination using Grocott staining confirmed the presence of Grocott-positive fungi within the vegetation, leading to a definitive diagnosis of prosthetic valve endocarditis (PVE) caused by Candida albicans; this management resulted in favorable outcomes. The present case suggests that fungal PVE can also complicate STEMI, and real-time 3D-TEE was instrumental in diagnosing and accurately assessing the vegetation in this condition.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 1","pages":"187-190"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Pancreatitis-Induced Takotsubo Cardiomyopathy in Exacerbated Chronic Renal Failure.","authors":"Jiangliu Xie, Yulu Yang, Yuanguo Chen","doi":"10.1536/ihj.24-343","DOIUrl":"10.1536/ihj.24-343","url":null,"abstract":"<p><p>A 66-year-old elderly woman undergoing regular dialysis for chronic renal failure was admitted to our hospital with acute pancreatitis. Coronary angiography revealed stress cardiomyopathy and cardiogenic shock. The patient was successfully treated with early Continuous Renal Replacement Therapy (CRRT). After 3 weeks of hospitalization, her left ventricular ejection fraction improved significantly.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 2","pages":"329-334"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Values of Echocardiographic Parameters Combined with Platelet Indices for the Sustained Opening of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants.","authors":"Dinghua Wen, Muqi Ye, Shaozhong Liu, Qiuling Wu, Xiaozhen Liu","doi":"10.1536/ihj.24-635","DOIUrl":"https://doi.org/10.1536/ihj.24-635","url":null,"abstract":"<p><p>Patent ductus arteriosus (PDA) is a prevalent congenital cardiac anomaly in neonates. It is characterized by substantial hemodynamic alterations owing to large shunt volumes and is referred to as hemodynamically significant PDA (hsPDA). hsPDA incidence is notably elevated in preterm infants, who are consequently at increased risk of severe organ complications and mortality. This study aimed to evaluate the predictive value of early echocardiographic parameters combined with platelet indices for predicting the persistence of hsPDA at 14 days postnatally. We conducted a retrospective analysis of clinical data from 120 very-low-birth-weight infants admitted to Zhongshan People's Hospital between May 2020 and August 2023, dividing them into the hsPDA (n = 46) and non-hsPDA (n = 74) groups based on echocardiography and clinical outcomes at 14 days. Univariate and multivariate logistic regression analyses identified the PDA diameter and left atrium-to-aorta ratio (LA/AO) as independent risk factors for persistent hsPDA, whereas the platelet distribution width (PDW) index emerged as a protective factor. Receiver operating characteristic curve analysis indicated that the area under the curve (AUC) values for the parameters of PDA diameter (0.7769, with a cut-off value of 2.81), LA/AO ratio (0.8964, with a cut-off value of 1.465), and PDW (0.7521, with a cut-off value of 15.58) were calculated. Meanwhile, the combination of these three parameters achieved the highest diagnostic efficiency (AUC = 0.9222). In summary, echocardiographic parameters, particularly the PDA diameter and LA/AO ratio, in conjunction with the PDW index, are effective predictors of persistent hsPDA in preterm infants. These findings offer valuable insights for the early clinical diagnosis of this condition.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 3","pages":"420-426"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errata: Phenogroups and Their Prognosis of Acute Decompensated Heart Failure with Preserved Ejection Fraction.","authors":"","doi":"10.1536/ihj.66-1_Errata","DOIUrl":"10.1536/ihj.66-1_Errata","url":null,"abstract":"<p><p>Several errors (shown with underlines) in the following list appeared in the article \"Phenogroups and Their Prognosis of Acute Decompensated Heart Failure with Preserved Ejection Fraction\" by Taro Makino, Yuya Ishihara, Masahide Harada, Yoshihiro Sobue, Eiichi Watanabe, Yukio Ozaki, Hideo Izawa (Vol. 65 No.5, 841-848, 2024).</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 1","pages":"191"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Novel Therapeutics for Pulmonary Arterial Hypertension.","authors":"Takayuki Fujiwara, Satoshi Ishii, Shun Minatsuki, Masaru Hatano, Norifumi Takeda","doi":"10.1536/ihj.24-615","DOIUrl":"10.1536/ihj.24-615","url":null,"abstract":"<p><p>Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressive obliteration of pulmonary arteries. Dysregulated bone morphogenetic protein (BMP) signaling pathway contributes to the development of PAH, and pulmonary vasodilators including endothelin receptor antagonists, phosphodiesterase 5 inhibitors, prostaglandins and soluble guanylate cyclase stimulators, dramatically improve the long-term prognosis. However, there still exist refractory patients who require continuous catecholamine support or lung transplantation, and the development of new treatment strategies targeting molecular mechanisms of PAH is highly anticipated. Sotatercept, a first-in-class activin signaling inhibitor, has recently been approved for the treatment of PAH, and it targets and restores an imbalance in activin-growth differentiation factor and BMP pathway signaling. In addition, treatment strategies targeting peroxisome proliferator-activated receptor-γ signaling, inflammatory and immune systems, DNA damage response and cellular senescence, and growth factor receptors including vascular endothelial growth factor and platelet-derived growth factor receptors, are being devised. In this review, we briefly summarize the recent advances in basic research paving the way for the development of more effective treatments for PAH and their potential in clinical therapeutic applications.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 1","pages":"3-12"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histone Demethylase PHF8 Confers Protection against Oxidative Stress and Cardiomyocyte Apoptosis in Heart Failure by Upregulating FOXA2.","authors":"Aike Fei, Li Li, Yanfei Liu, Zhe Lv, Jing Jin","doi":"10.1536/ihj.24-268","DOIUrl":"10.1536/ihj.24-268","url":null,"abstract":"<p><p>Oxidative stress and cardiomyocyte apoptosis are hallmarks of heart failure (HF) development. Plant homeodomain finger protein 8 (PHF8) is a histone demethylase downregulated in failing human hearts. Nevertheless, the potential role of PHF8 in HF remains unclear. Therefore, this study aimed to explore the biological action and molecular mechanism of PHF8 in HF.A rat model of left anterior descending coronary artery (LAD) ligation-induced HF and a cardiomyocyte model of oxygen-glucose deprivation/reperfusion (OGD/R) were developed after gain- or loss-of-function experiments in rats and cardiomyocytes, respectively. Heart function indexes, such as left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular ejection fraction, and left ventricular fractional shortening, were detected. Changes in myocardial tissues were examined by pathological staining. Cardiomyocyte apoptosis and oxidative stress markers, such as malondialdehyde, reactive oxygen species, superoxide dismutase, and catalase, were examined. The relationship between PHF8 and forkhead box A2 (FOXA2) was analyzed by luciferase and chromatin immunoprecipitation-quantitative polymerase chain reaction assays.PHF8 was downregulated in LAD-ligated rats and OGD/R-exposed cardiomyocytes. Following PHF8 upregulation, pathological changes in myocardial tissues and heart dysfunction were improved in LAD-ligated rats. Importantly, cardiomyocyte apoptosis and oxidative stress were diminished in vivo and in vitro upon PHF8 upregulation. Mechanistically, PHF8 increased FOXA2 expression in a histone demethylase-dependent manner. FOXA2 silencing abrogated the protective effect of PHF8 upregulation on cardiomyocytes against OGD/R-induced apoptosis and oxidative stress.PHF8 exerts protective functions against cardiomyocyte apoptosis, oxidative stress, and heart dysfunction in HF, in correlation with FOXA2 upregulation. These results suggest that the PHF8/FOXA2 axis may be a promising therapeutic target to prevent HF.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 1","pages":"114-125"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Sarcopenia in Men Versus Women with Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction.","authors":"Takanari Kimura, Shunsuke Tamaki, Takahisa Yamada, Tetsuya Watanabe, Masatake Fukunami, Yoshio Yasumura, Akito Nakagawa, Yusuke Nakagawa, Masamichi Yano, Takaharu Hayashi, Shungo Hikoso, Daisaku Nakatani, Yohei Sotomi, Yasushi Sakata","doi":"10.1536/ihj.24-475","DOIUrl":"https://doi.org/10.1536/ihj.24-475","url":null,"abstract":"<p><p>Sarcopenia is associated with poor prognosis in chronic heart failure. The fat-free mass index (FFMI) is an indicator of resting energy expenditure and is used to clinically diagnose sarcopenia. We aimed to elucidate the prognostic impact of sarcopenia diagnosed via FFMI by sex in patients admitted for acute decompensated heart failure (ADHF) and preserved left ventricular ejection fraction (LVEF).Patients' data were extracted from the Prospective Multicenter Observational Study of Patients with Heart Failure with Preserved Ejection Fraction study, a prospective multicenter observational registry for patients with ADHF with LVEF ≥ 50% in Osaka. We studied 831 patients who survived and were discharged. Fat-free mass (FFM) was estimated using the Forbes formula (FFM [kg] = 7.38 + 0.02908 × urinary creatinine [mg/day]) and normalized to the square of the patient's height in meters to calculate the FFMI at discharge. Sarcopenia was defined as FFMI < 17 kg/m² in men and < 15 kg/m² in women.During the follow-up period of 3.3 ± 1.6 years, 351 patients died. Multivariate Cox analysis showed that sarcopenia was independently associated with all-cause mortality in women (P = 0.003) but not in men (P = 0.118) after adjustment for major confounders. Although sarcopenia was not associated with cardiac death in either sex, it was independently associated with noncardiac death in men (P = 0.048) and women (P < 0.001).Sarcopenia diagnosed via FFMI was associated with poor clinical outcomes in patients with ADHF and preserved LVEF, primarily attributable to its association with noncardiac death, regardless of sex.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 3","pages":"363-374"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Controlled Study on the Clinical Efficacy of Ginkgo Biloba Combined with Nicorandil in Patients with HFmrEF.","authors":"Xiang Gao, Fangyuan Liu, Xiaozhen Han, Shan Tang, Dingding Shen, Jia Zhang, Chuanliang Liu","doi":"10.1536/ihj.24-316","DOIUrl":"10.1536/ihj.24-316","url":null,"abstract":"<p><p>This study aimed to explore the clinical efficacy of Ginkgo biloba combined with Nicorandil in patients with heart failure who have a mild decrease in ejection fraction (HFmrEF).A total of 316 patients with HFmrEF were selected and randomly assigned to either a control group or a combination of the Ginkgo biloba and Nicorandil group, each group consisting of 158 patients. The control group received standard secondary preventive treatment, while patients in the combination group received oral Ginkgo biloba and Nicorandil based on stable conventional treatment. Both groups were treated continuously for six months. The age, sex, body mass index (BMI), New York Heart Association cardiac function classification, history of coronary heart disease, hypertension, diabetes, atrial fibrillation, smoking, left ventricular ejection fractions (LVEF), heart rate, glycosylated hemoglobin (HbA1c), and combined drug use of the patients in the two groups were recorded. The efficacy endpoints were BMI, heart rate, blood lipid levels, fasting blood glucose, renal function, HbA1c, N-terminal pro-brain natriuretic peptide (NT-proBNP), LVEF, cardiopulmonary exercise testing parameters, 6-minute walking distance (6MWD), and the Kansas City Cardiomyopathy Questionnaire (KCCQ) score after six months of treatment. The incidence of adverse reactions in the two groups was recorded.After six months of treatment, the BMI, heart rate, NT-proBNP, low-density lipoprotein cholesterol, triglyceride, creatinine, fasting blood glucose, and HbA1c levels of patients in the Ginkgo biloba combined with Nicorandil group were lower than those in the control group (P < 0.05). The LVEF, high-density lipoprotein cholesterol, VO2peak, oxygen uptake efficiency slope, 6MWD, and KCCQ scores were higher in the Ginkgo biloba combined with Nicorandil group than in the control group (P < 0.05). There was no statistically significant difference between the two groups of patients (P > 0.05) in the incidence of hypotension, hypoglycemia, hypokalemia, headache, and hospitalization due to worsening heart failure.Ginkgo biloba combined with Nicorandil can effectively improve heart function, blood lipid levels, blood glucose levels, renal function, exercise tolerance, and health-related quality of life in patients with HFmrEF. Because there were no significant adverse reactions, they can be safely used.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 1","pages":"74-80"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unrecognized Diversity in the Effects of Cardiac Rehabilitation by Age in Patients with Heart Failure.","authors":"Kohsaku Goto, Eisuke Amiya","doi":"10.1536/ihj.24-742","DOIUrl":"https://doi.org/10.1536/ihj.24-742","url":null,"abstract":"","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"66 1","pages":"1-2"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}